| abstract |
Disclosed is an improved pharmaceutical composition having reduced hygroscopicity of a pharmaceutical montelukast which is a leukotriene antagonist, an asthma drug, and an allergy drug. A pharmaceutical composition comprising a crystalline form of montelukast represented by the following formula in the free acid state in an effective amount of a leukotriene antagonist. The compound is preferably microcrystalline with an average particle size of less than 200 μm. The composition is preferably formulated into a solid dosage form in the form of a tablet, capsule, pellet, or inhalable powder. [Selection figure] None |